Unmet Needs, Future Directions, and Clinical Pearls in mCRPC

Dr. Freedland closes his discussion by highlighting remaining unmet needs in mCRPC treatment and providing some clinical pearls for community oncologists treating patients with the disease.

EP: 1.Case Presentation: A 67-Year-Old-Man with Metastatic Prostate Cancer

EP: 2.Available Systemic Therapy Options for Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel and AR-Targeted Therapy

EP: 3.Factors for Consideration When Selecting Treatments for Patients with mCRPC

EP: 4.The Impact of Using AR Pathway Inhibitors and Docetaxel in Early Treatment of Prostate Cancer

Now Viewing

EP: 5.Unmet Needs, Future Directions, and Clinical Pearls in mCRPC

Related Videos

Related Content

Advertisement

January 15th 2025

EU approves Mona Lisa 2.0 robotic system for prostate cancer

Hannah Clarke

The Mona Lisa 2.0 platform has been previously approved in the US, Australia, and Singapore.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

January 9th 2025

Dual-masked PSMA-targeting T-cell engager shows promise in mCRPC

Hannah Clarke

Following an initial dose of VIR-5500 of 120 µg/kg or higher, all patients achieved a PSA reduction.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

January 1st 2025

2024 Urology Times pipeline report

Jason M. Broderick Hannah Clarke Brittany Lovely

Catch up on all the notable drug and device approvals in urology over the past year.

December 28th 2024

Top 10 prostate cancer articles and videos of 2024

Benjamin P. Saylor

As the year comes to a close, we revisit some of this year’s top content on prostate cancer.

Related Content

Advertisement

January 15th 2025

EU approves Mona Lisa 2.0 robotic system for prostate cancer

Hannah Clarke

The Mona Lisa 2.0 platform has been previously approved in the US, Australia, and Singapore.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

January 9th 2025

Dual-masked PSMA-targeting T-cell engager shows promise in mCRPC

Hannah Clarke

Following an initial dose of VIR-5500 of 120 µg/kg or higher, all patients achieved a PSA reduction.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

January 1st 2025

2024 Urology Times pipeline report

Jason M. Broderick Hannah Clarke Brittany Lovely

Catch up on all the notable drug and device approvals in urology over the past year.

December 28th 2024

Top 10 prostate cancer articles and videos of 2024

Benjamin P. Saylor

As the year comes to a close, we revisit some of this year’s top content on prostate cancer.